688321 微芯生物
已收盘 07-15 15:00:01
资讯
新帖
简况
微芯生物涨5.06% 政策催化与资金博弈推动反弹
智选洞察 · 05:20
微芯生物涨5.06% 政策催化与资金博弈推动反弹
每周股票复盘:微芯生物(688321)西达本胺III期临床试验获顶线分析数据
证券之星 · 07-12 18:13
每周股票复盘:微芯生物(688321)西达本胺III期临床试验获顶线分析数据
微芯生物涨5.05% 政策博弈与估值分歧共振
智选洞察 · 07-11
微芯生物涨5.05% 政策博弈与估值分歧共振
非酒精性脂肪性肝炎(NASH)概念盘中拉升,微芯生物涨9.42%
市场透视 · 07-10
非酒精性脂肪性肝炎(NASH)概念盘中拉升,微芯生物涨9.42%
肿瘤治疗概念盘中拉升,微芯生物涨8.31%
市场透视 · 07-10
肿瘤治疗概念盘中拉升,微芯生物涨8.31%
【创新药概念股反复活跃,塞力医疗、康辰药业触及涨停】创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。
金融界 · 07-10
【创新药概念股反复活跃,塞力医疗、康辰药业触及涨停】创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。
微芯生物涨5.62% 政策红利与资金博弈推动异动
智选洞察 · 07-10
微芯生物涨5.62% 政策红利与资金博弈推动异动
微芯生物股价小幅震荡 西达本胺III期临床数据出炉
金融界 · 07-09
微芯生物股价小幅震荡 西达本胺III期临床数据出炉
医药行业日报:诺和诺德向欧盟递交司美格鲁肽7.2毫克新剂量申请
太平洋证券股份... · 07-09
医药行业日报:诺和诺德向欧盟递交司美格鲁肽7.2毫克新剂量申请
微芯生物(688321.SH):西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获顶线分析数据
智通财经 · 07-09
微芯生物(688321.SH):西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获顶线分析数据
微芯生物获得发明专利授权:“一种杂环化合物及其应用”
证券之星 · 07-07
微芯生物获得发明专利授权:“一种杂环化合物及其应用”
7月7日微芯生物涨5.81%,民生加银精选混合基金重仓该股
证券之星 · 07-07
7月7日微芯生物涨5.81%,民生加银精选混合基金重仓该股
微芯生物涨5.81%,太平洋二个月前给出“买入”评级
证券之星 · 07-07
微芯生物涨5.81%,太平洋二个月前给出“买入”评级
创新药概念异动拉升 广生堂、微芯生物涨超10%
E公司 · 07-07
创新药概念异动拉升 广生堂、微芯生物涨超10%
非酒精性脂肪性肝炎(NASH)概念盘中拉升,微芯生物涨11.74%
市场透视 · 07-07
非酒精性脂肪性肝炎(NASH)概念盘中拉升,微芯生物涨11.74%
非酒精性脂肪性肝炎(NASH)概念盘中拉升,诺泰生物涨3.58%
市场透视 · 07-04
非酒精性脂肪性肝炎(NASH)概念盘中拉升,诺泰生物涨3.58%
微芯生物:生产经营正常 无应披露而未披露的重大信息
蓝鲸财经 · 07-03
微芯生物:生产经营正常 无应披露而未披露的重大信息
7月3日微芯生物(688321)龙虎榜数据:机构净买入1.48亿元,北向资金净卖出846.55万元
证券之星 · 07-03
7月3日微芯生物(688321)龙虎榜数据:机构净买入1.48亿元,北向资金净卖出846.55万元
7月3日微芯生物涨8.79%,民生加银精选混合基金重仓该股
证券之星 · 07-03
7月3日微芯生物涨8.79%,民生加银精选混合基金重仓该股
猴痘概念盘中拉升,微芯生物涨8.19%
市场透视 · 07-03
猴痘概念盘中拉升,微芯生物涨8.19%
加载更多
公司概况
公司名称:
深圳微芯生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2019-08-12
主营业务:
深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用。公司的主要产品是爱谱沙(西达本胺)、双洛平(西格列他钠)、西奥罗尼、其他在研产品。
发行价格:
20.43
{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":35.77,"timestamp":1752562801000,"preClose":33.98,"halted":0,"volume":26164818,"delay":0,"changeRate":0.0527,"floatShares":408000000,"shares":408000000,"eps":-0.2831,"marketStatus":"已收盘","change":1.79,"latestTime":"07-15 15:00:01","open":33.49,"high":36.19,"low":33,"amount":911000000,"amplitude":0.0939,"askPrice":35.77,"askSize":202,"bidPrice":35.76,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-0.2831,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752629400000},"marketStatusCode":5,"adr":0,"adjPreClose":33.98,"symbolType":"stock_kcb","openAndCloseTimeList":[[1752543000000,1752550200000],[1752555600000,1752562800000]],"highLimit":37.38,"lowLimit":30.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407796477,"isCdr":false,"pbRate":10.14,"roa":"--","roe":"--","epsLYR":-0.2808,"committee":0.101274,"marketValue":14587000000,"turnoverRate":0.0642,"status":0,"afterMarket":{"amount":17885,"volume":500,"close":35.77,"buyVolume":0,"sellVolume":0,"time":1752564838025,"indexStatus":"已收盘 07-15 15:30:00","preClose":33.98},"floatMarketCap":14587000000},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2551155576","title":"微芯生物涨5.06% 政策催化与资金博弈推动反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2551155576","media":"智选洞察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551155576?lang=zh_cn&edition=full","pubTime":"2025-07-15 13:20","pubTimestamp":1752556827,"startTime":"0","endTime":"0","summary":"微芯生物股价大幅上涨,最新价35.70元/股,涨幅达5.06%。政策催化与资金博弈双向角力微芯生物近期股价波动与政策预期及资金流向紧密相关。7月1日创新药支持政策公布后,单日主力资金净流入9853万元推动股价大涨11.44%,但次日机构与沪股通抛售3.55亿元,资金快进快出特征明显。此外,生物医药板块上半年业绩预喜企业增多,行业情绪回暖带动资金轮动。2025年前三季度营收1.62亿元,同比增长24.24%,但净利润亏损1915万元,显示政策红利尚未转化为盈利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715132030a6aa49c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715132030a6aa49c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2551916555","title":"每周股票复盘:微芯生物(688321)西达本胺III期临床试验获顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2551916555","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551916555?lang=zh_cn&edition=full","pubTime":"2025-07-13 02:13","pubTimestamp":1752343989,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘,微芯生物报收于33.8元,较上周的31.0元上涨9.03%。本周,微芯生物7月7日盘中最高价报34.95元,股价触及近一年最高点。本周关注点公司公告汇总:西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获得顶线分析数据公司公告汇总微芯生物自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤的关键性III期临床试验获得顶线分析数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300000279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239","BK1576","03347","BK1583","BK1141"],"gpt_icon":0},{"id":"2550605926","title":"微芯生物涨5.05% 政策博弈与估值分歧共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2550605926","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550605926?lang=zh_cn&edition=full","pubTime":"2025-07-11 09:50","pubTimestamp":1752198655,"startTime":"0","endTime":"0","summary":"微芯生物股价大幅上涨,最新价34.32元/股,涨跌幅为5.05%。政策博弈与估值分歧共振微芯生物近期股价波动呈现典型政策驱动特征。研发转化效率决定估值重构长期来看,微芯生物面临收入结构单一与估值溢价的双重挑战。2025年前三季度营收1.62亿元同比增长24.24%,显示政策红利开始释放,但市净率9.73倍较行业均值显著偏高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711095100a6a2a228&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711095100a6a2a228&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2550693603","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升,微芯生物涨9.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550693603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550693603?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:02","pubTimestamp":1752112970,"startTime":"0","endTime":"0","summary":"07月10日,非酒精性脂肪性肝炎(NASH)概念盘中拉升,截至10点02分,非酒精性脂肪性肝炎(NASH)概念整体指数上涨2.01%,报1179.450点。从个股上来看,该概念的成分股中,微芯生物涨9.42%,众生药业、康弘药业、华东医药涨幅居前。从资金上来看,截止发稿,非酒精性脂肪性肝炎(NASH)概念主力净流入为6881.41万,其中微芯生物受到资金热捧,主力净流入4978.04万;拉长时间线来看,该板块近20日主力资金净流入-14.11亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710100250a4416fcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710100250a4416fcc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2550698994","title":"肿瘤治疗概念盘中拉升,微芯生物涨8.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550698994","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550698994?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:51","pubTimestamp":1752112307,"startTime":"0","endTime":"0","summary":"07月10日,肿瘤治疗概念盘中拉升,截至09点51分,肿瘤治疗概念整体指数上涨1.00%,报1558.010点。从个股上来看,该概念的成分股中,微芯生物涨8.31%,安科生物、誉衡药业2只股涨幅超过5%。从资金上来看,截止发稿,肿瘤治疗概念主力净流入为2.23亿,其中恒瑞医药受到资金热捧,主力净流入8318.81万;拉长时间线来看,该板块近20日主力资金净流入-87.18亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710095147a6a07838&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710095147a6a07838&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2550660707","title":"【创新药概念股反复活跃,塞力医疗、康辰药业触及涨停】创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2550660707","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550660707?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:46","pubTimestamp":1752111976,"startTime":"0","endTime":"0","summary":"创新药概念股反复活跃,塞力医疗、康辰药业触及涨停,海思科涨超7%,先达股份、华纳药厂、微芯生物纷纷上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f4ae4484572f275cf3aa38bb605c2821","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/10094651600059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["603086","688799","BK0077","603590","BK0229","002653","688321","BK1574","BK0028","BK1161","BK0188","06978","159992","BK0239","BK0250","BK0033","603716"],"gpt_icon":0},{"id":"2550999698","title":"微芯生物涨5.62% 政策红利与资金博弈推动异动","url":"https://stock-news.laohu8.com/highlight/detail?id=2550999698","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550999698?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:30","pubTimestamp":1752111054,"startTime":"0","endTime":"0","summary":"微芯生物股价今日早盘显著攀升,截至09点30分,最新价报33.06元,上涨5.62%。政策红利与资金博弈交织引发异动微芯生物近期股价波动受政策与资金面双重驱动。7月1日创新药支持政策落地后,单日主力资金净流入9853万元推动股价大涨11.44%,但随后四日累计净流出逾1.5亿元,反映机构兑现意愿强烈。2025年前三季度营收1.62亿元同比增长24.24%,显示政策红利释放效果,但归属净利润亏损1915万元,商业化能力仍待验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710093502a4415fe6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710093502a4415fe6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2550657788","title":"微芯生物股价小幅震荡 西达本胺III期临床数据出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2550657788","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550657788?lang=zh_cn&edition=full","pubTime":"2025-07-10 01:53","pubTimestamp":1752083586,"startTime":"0","endTime":"0","summary":"截至2025年7月9日15时,微芯生物股价报31.30元,较前一交易日下跌0.32%,成交额达6.18亿元。7月9日,微芯生物公告称,其自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤的关键性III期临床试验获得最终结果的顶线分析数据,试验组无事件生存期显著优于对照组,达到主要研究终点。公司表示,正在准备该适应症的常规批准申报。2025年7月9日,微芯生物主力资金净流入3693.05万元,占流通市值的0.29%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/10015351595901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["III","BK4134","688321","BK0239"],"gpt_icon":0},{"id":"2550618570","title":"医药行业日报:诺和诺德向欧盟递交司美格鲁肽7.2毫克新剂量申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2550618570","media":"太平洋证券股份...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550618570?lang=zh_cn&edition=full","pubTime":"2025-07-10 00:00","pubTimestamp":1752076800,"startTime":"0","endTime":"0","summary":"行业要闻:近日,诺和诺德宣布,公司已向欧洲药品管理局提交其重磅疗法Wegovy7.2 毫克新剂量的监管申请,此次申请主要基于STEP UP 试验和STEP UP T2D 试验。数据显示,该剂量的安全性良好,与此前获批的2.4 毫克剂量及其他司美格鲁肽临床研究结果一致。此次申请旨在拓展Wegovy 的治疗剂量选项,为肥胖患者提供更高剂量的治疗方案,进一步提升体重管理效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710140727953d11f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710140727953d11f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688690","LU0154236417.USD","NVO","BK4532","BK4585","BK4588","BK4599","IE00BZ1G4Q59.USD","BK4007","LU1093756325.SGD","LU1093756168.USD","601607","603087","688321","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2550341689","title":"微芯生物(688321.SH):西达本胺一线治疗弥漫大B细胞淋巴瘤的III期临床试验获顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2550341689","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550341689?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:02","pubTimestamp":1752048130,"startTime":"0","endTime":"0","summary":"智通财经APP讯,微芯生物 公告,公司自主研发的西达本胺针对一线治疗弥漫大B细胞淋巴瘤关键性III期临床试验已于近日获得最终结果的顶线分析数据,试验组无事件生存期显著优于对照组,达成研究主要终点。西达本胺作用于表观遗传相关靶点组蛋白去乙酰化酶。此次顶线分析中,试验组无事件生存期较对照组展现具统计学显著意义的差异,进一步验证了西达本胺联合方案可为初治MYC和BCL2双表达DLBCL患者带来显著且可持续的疗效,且安全性良好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688321","03347","III","BK1583","BK0239","BK4134","BK1576","BK1141"],"gpt_icon":0},{"id":"2549104552","title":"微芯生物获得发明专利授权:“一种杂环化合物及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2549104552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549104552?lang=zh_cn&edition=full","pubTime":"2025-07-08 02:42","pubTimestamp":1751913761,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示微芯生物新获得一项发明专利授权,专利名为“一种杂环化合物及其应用”,专利申请号为CN202280032814.6,授权日为2025年7月8日。今年以来微芯生物新获得专利授权3个,较去年同期减少了40%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070800002383.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2549589346","title":"7月7日微芯生物涨5.81%,民生加银精选混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2549589346","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549589346?lang=zh_cn&edition=full","pubTime":"2025-07-07 16:23","pubTimestamp":1751876625,"startTime":"0","endTime":"0","summary":"证券之星消息,7月7日微芯生物涨5.81%创60日新高,收盘报32.8元,换手率8.27%,成交量33.74万手,成交额11.21亿元。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为民生加银基金的民生加银精选混合。刘霄汉在任的基金产品包括:民生加银品质消费股票A,管理时间为2021年8月13日至今,期间收益率为-43.51%;民生加银创新成长混合A,管理时间为2024年8月28日至今,期间收益率为35.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070700020816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2549898705","title":"微芯生物涨5.81%,太平洋二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2549898705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549898705?lang=zh_cn&edition=full","pubTime":"2025-07-07 16:23","pubTimestamp":1751876617,"startTime":"0","endTime":"0","summary":"今日微芯生物(688321)涨5.81%,收盘报32.8元。2025年5月2日,太平洋研究员谭紫媚,张懿发布了对微芯生物的研报《微芯生物:核心产品增长稳健,重点临床稳步推进》,该研报对微芯生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为75.06%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华西证券的孙子豪、崔文亮。微芯生物(688321)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070700020810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","688321"],"gpt_icon":0},{"id":"2549308470","title":"创新药概念异动拉升 广生堂、微芯生物涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549308470","media":"E公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549308470?lang=zh_cn&edition=full","pubTime":"2025-07-07 09:44","pubTimestamp":1751852651,"startTime":"0","endTime":"0","summary":"人民财讯7月7日电,创新药概念异动拉升,广生堂、微芯生物涨超10%,前沿生物、华纳药厂、泽璟制药、圣诺生物等股纷纷拉升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707094412a43ab2d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707094412a43ab2d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688117","688221","688321","159992","BK0239","688799","300436"],"gpt_icon":0},{"id":"2549081993","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升,微芯生物涨11.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549081993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549081993?lang=zh_cn&edition=full","pubTime":"2025-07-07 09:38","pubTimestamp":1751852311,"startTime":"0","endTime":"0","summary":"07月07日,非酒精性脂肪性肝炎(NASH)概念盘中拉升,截至09点38分,非酒精性脂肪性肝炎(NASH)概念整体指数上涨2.06%,报1182.190点。从个股上来看,该概念的成分股中,微芯生物涨11.74%,福瑞股份、康弘药业、天士力涨幅居前。从资金上来看,截止发稿,非酒精性脂肪性肝炎(NASH)概念主力净流入为2432.22万,其中微芯生物受到资金热捧,主力净流入3957.94万;拉长时间线来看,该板块近20日主力资金净流入-9.49亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507070938319538f42c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507070938319538f42c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","BK0012","BK0188","BK0028","688321","BK0196","BK0239","600535"],"gpt_icon":0},{"id":"2548332205","title":"非酒精性脂肪性肝炎(NASH)概念盘中拉升,诺泰生物涨3.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548332205","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548332205?lang=zh_cn&edition=full","pubTime":"2025-07-04 09:49","pubTimestamp":1751593742,"startTime":"0","endTime":"0","summary":"07月04日,非酒精性脂肪性肝炎(NASH)概念盘中拉升,截至09点48分,非酒精性脂肪性肝炎(NASH)概念整体指数上涨0.61%,报1154.630点。从个股上来看,该概念的成分股中,诺泰生物涨3.58%,康弘药业、微芯生物、迈瑞医疗涨幅居前。从资金上来看,截止发稿,非酒精性脂肪性肝炎(NASH)概念主力净流入为1391.18万,其中迈瑞医疗受到资金热捧,主力净流入5283.96万;拉长时间线来看,该板块近20日主力资金净流入-8.25亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070409490297994967&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070409490297994967&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239","688076"],"gpt_icon":0},{"id":"2548808091","title":"微芯生物:生产经营正常 无应披露而未披露的重大信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2548808091","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548808091?lang=zh_cn&edition=full","pubTime":"2025-07-03 18:15","pubTimestamp":1751537707,"startTime":"0","endTime":"0","summary":"《科创板日报》3日讯,微芯生物(688321.SH)公告称,公司股票交易价格连续三个交易日收盘价格涨幅偏离值累计达到30%,属于股票交易异常波动情形。经自查,公司目前生产经营活动一切正常,不存在应披露而未披露的重大信息。公司提醒投资者注意二级市场交易风险,理性决策,审慎投资。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070318171597987873&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070318171597987873&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2548872044","title":"7月3日微芯生物(688321)龙虎榜数据:机构净买入1.48亿元,北向资金净卖出846.55万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548872044","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548872044?lang=zh_cn&edition=full","pubTime":"2025-07-03 17:17","pubTimestamp":1751534267,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2025年7月3日公布的交易公开信息显示,微芯生物因有价格涨跌幅限制的连续3个交易日内收盘价格涨幅偏离值累计达到30%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年7月3日收盘,微芯生物报收于30.82元,上涨8.79%,换手率8.33%,成交量33.98万手,成交额10.37亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入1.48亿元,北向资金合计净卖出846.55万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300027907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2548760408","title":"7月3日微芯生物涨8.79%,民生加银精选混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2548760408","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548760408?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:27","pubTimestamp":1751531276,"startTime":"0","endTime":"0","summary":"证券之星消息,7月3日微芯生物涨8.79%创60日新高,收盘报30.82元,换手率8.33%,成交量33.98万手,成交额10.37亿元。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为民生加银基金的民生加银精选混合。刘霄汉在任的基金产品包括:民生加银品质消费股票A,管理时间为2021年8月13日至今,期间收益率为-43.91%;民生加银创新成长混合A,管理时间为2024年8月28日至今,期间收益率为34.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070300026143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2548840419","title":"猴痘概念盘中拉升,微芯生物涨8.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548840419","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548840419?lang=zh_cn&edition=full","pubTime":"2025-07-03 10:00","pubTimestamp":1751508040,"startTime":"0","endTime":"0","summary":"07月03日,猴痘概念盘中拉升,截至10点00分,猴痘概念整体指数上涨1.12%,报1001.550点。从个股上来看,该概念的成分股中,微芯生物涨8.19%,热景生物涨幅超过5%。从资金上来看,截止发稿,猴痘概念主力净流入为-2257.12万,其中热景生物受到资金热捧,主力净流入2413.19万;拉长时间线来看,该板块近20日主力资金净流入-55.44亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507031000409797ff41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507031000409797ff41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752597218022,"stockEarnings":[{"period":"1week","weight":0.1392},{"period":"1month","weight":0.5606},{"period":"3month","weight":1.1999},{"period":"6month","weight":1.0629},{"period":"1year","weight":1.0906},{"period":"ytd","weight":0.9252}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.0379},{"period":"3month","weight":0.0699},{"period":"6month","weight":0.0831},{"period":"1year","weight":0.1785},{"period":"ytd","weight":0.0457}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17684人(较上一季度减少1.85%)","perCapita":"23060股","listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","registeredCapital":"40779万元","survey":" 深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用。公司的主要产品是爱谱沙(西达本胺)、双洛平(西格列他钠)、西奥罗尼、其他在研产品。","listedPrice":20.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}